Magnesium Hydroxide (Brucite)

03/01/1989 - "A randomized, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of dual topical therapy with zinc chloride spray and magnesium hydroxide ointment in healing incisional wounds. "
03/01/1989 - "Zinc chloride spray--magnesium hydroxide ointment dual topical regimen in the treatment of obstetric and gynecologic incisional wounds."

01/01/1982 - "We investigated the safety and efficacy of magnesium hydroxide as a phosphate binder in patients with end-stage renal disease on maintenance hemodialysis, 9 volunteers participated in a four-phase study during which each ingested (1) no phosphate binders, (2) magnesium hydroxide (Mg(OH)2) alone, (3) Mg(OH)2 and aluminum hydroxide (A1(OH)3) together and (4) A1(OH)3 alone. "

06/01/1998 - "This report concerns the case of a 39-year-old pharmacist who self-mediated for peptic ulcer disease with high doses of a potent antacid containing aluminum and magnesium hydroxide. "
01/01/1947 - "Colloidal aluminum hydroxide gel and magnesium hydroxide in the management of peptic ulcers."
06/01/1998 - "Antacids containing aluminum and magnesium hydroxide are widely used nonprescription agents for treatment of gastritis and peptic ulcer disease. "
08/01/1997 - "Antacids, such as aluminium-magnesium hydroxide (AIMg(OH)3), or H2-receptor antagonists, such as ranitidine, are common drugs used for treating peptic ulcer disease and acid-related symptoms. "
01/01/1987 - "Sucralfate, one of the newer drugs shown to be effective in the treatment of peptic ulcer and esophagitis; cholestyramine, a known bile acid binder; and commercial antacid preparations of pure aluminum hydroxide, pure magnesium hydroxide, and a combination of aluminum hydroxide, magnesium hydroxide, and magnesium carbonate were tested in vitro for bile acid-binding capacity. "

09/10/1991 - "In a randomized, multicenter, double-blind study involving a total of 97 patients, the effectiveness and tolerance of Gelofalk, a new type of antacid combination comprising smectite--a natural alum earth, the specific molecular structure of which permits it to bind aggressive substances particularly well--aluminium hydroxide and magnesium hydroxide were investigated in comparison with a commercially available aluminium hydroxide antacid used by patients with gastritis, esophagitis and functional upper abdominal complaints over a treatment period of 4 weeks. "
01/01/1987 - "Sucralfate, one of the newer drugs shown to be effective in the treatment of peptic ulcer and esophagitis; cholestyramine, a known bile acid binder; and commercial antacid preparations of pure aluminum hydroxide, pure magnesium hydroxide, and a combination of aluminum hydroxide, magnesium hydroxide, and magnesium carbonate were tested in vitro for bile acid-binding capacity. "

05/01/1988 - "Gastric or duodenal ulcers were treated with 300 mg ranitidin and an aluminium-magnesium-hydroxide-containing antacid with an acid binding capacity of 280 mval/day. "
01/01/1982 - "Acid rebound and gastrin release will also be induced in duodenal ulcer patients by magnesium hydroxide. "
01/01/1972 - "[Influence of gastric juice neutralization using magnesium hydroxide on gastrin concentration in patients with duodenal ulcer]."
11/01/1986 - "The effect of cimetidine (400 mg at night) and of low-dose antacid (400 mg of aluminum hydroxide plus 400 mg of magnesium hydroxide four times a day) given alone or in combination was assessed in a double-blind double-dummy endoscopic trial on prevention of duodenal ulcer (DU). "
12/01/1984 - "The incidence of duodenal ulcer relapse after initial therapy with concentrated aluminium-magnesium hydroxide (Maalox 70) or cimetidine (Tagamet) was investigated in a one-year follow-up study. "